X

Fresenius Kabi Oncology Ltd Stock Analysis

Small Cap
Evaluated by 475 users | BSE: 532545 | NSE: FKONCO |
Pharmaceuticals & Drugs
Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed  Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed 13.27%7.36%4.02%10.76%-11.01%-16.23%-4.22%3.12%8.66%4.31%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 411413527596408464542624703660
Y-o-Y Gr. Rt.-0.4%27.6%13.2%-31.6%13.7%16.7%15.2%12.7%-6.2%
Adjusted EPS (Rs.) 5.083.011.275.39-6.42-9.32-3.350.162.930.77
Y-o-Y Gr. Rt.--40.8%-57.8%324.4%-219.1%NANANA1731.3%-73.7%
Book Value per Share (Rs.) 31.134.237.4542.5535.5130.6725.8825.7526.9123.9
Adjusted Net Profit 80.447.620.185.4-102-159-572.849.813.1
Net Op. Cash Flow (Rs. Cr.) 55.850174127-52.7-1217.9-39.111298.4
Debt to Cash Flow from Ops 4.826.650.851.1-5.89-2.8853.14-13.314.254.7
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Fresenius Kabi Oncology Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 5.4%10.1%6.8%-6.2%
Adjusted EPS -18.9%NANA-73.7%
Book Value per Share -2.9-7.6-2.6-11.2
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) 17.789.213.5413.49-16.46-29.28-11.850.6311.113.03
Operating Profit Margin (%) 24.7717.9212.5923.98-18.24-20.61.1413.9119.0613.84
Net Profit Margin (%) 19.5411.533.8114.31-24.91-34.19-10.530.447.081.99
Debt to Equity 0.550.620.250.210.550.670.961.191.041.14
Working Capital Days 402452374353575523438409427473
Cash Conversion Cycle 173222186170267214198185176168
Entity Percentage Holding
Promoters 97.05%
Non-Institutions 2.94%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed  Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia,

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed  Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela, Mexico, and many more.

The manufacturing facilities are located in Bordon (U.K.), Kalyani (India) and Baddi (India). These plants are approved by the regulatory bodies of countries like Brazil, Colombia, Malaysia, Turkey, Pakistan, Ukraine, Sudan, Belarus Hungary, Jordan, Zimbabwe, Yemen.

Products

APIs- It manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Oncology- Under this it has created drugs like Intaxel, Nanoxel.

Other range of generic products offered by Fresenius Kabi Oncology includes, Taxane Analogues, Alkylating Agents, Anti-Metabolites, Cytostatic Antibiotics, Cytostatic hormone therapies.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback